*India has emrged as the medial tourism hub of the world providing cost-effective treatments with the latest technology enabled by several pathbreaking reforms and provisions. *Access to affordable HIV treatment from India is one of the greatest success stories in medicine. India is one of the biggest suppliers of low-cost vaccines in the world. * Because of the low price and high quality, Indian medicines are preferred worldwide, thereby rightly making the country the ‘Pharmacy of the World’. * India has been traditionally quite strong in the pharma sector, with a low cost of manufacturing (30%–35% lower than in the US and Europe), cost-efficient R&D (about 87% less than in developed markets), and cheap skilled labour. * On December 21, 2020, MoU was signed between Tata Memorial Centre of India and Vietnam National Cancer Hospital to promote exchanges in the areas of training and scientific research, health care services, collaboration in diagnosis and treatment for cancer patients. * and treatment for cancer patients.​ The total market size of the Indian Pharma Industry is expected to reach US$ 130 billion by 2030 and US$ 450 billion market by 2047. * The domestic pharmaceutical industry would likely reach US$ 57 billion by FY25 and see an increase in operating margins of 100-150 basis points (bps). * India has the largest number of USFDA-compliant pharmaceutical plants outside the US and over 2,000 WHO-GMP approved facilities, serving demand from 150+ countries worldwide, with 10,500+ manufacturing facilities.​ * The Ministry's scheme “Strengthening of Pharmaceutical Industry (SPI)" with a total financial outlay of Rs. 500 crore (US$ 60.9 million) extends support required to existing pharma clusters and MSMEs across the country to improve their productivity, quality and sustainability. *The Government has set a target to increase the number of Pradhan Mantri Bhartiya Jan Aushadhi Kendras to 10,500 by March 2025. The product basket of PMBJP comprises 1,451 drugs and 240 surgical instruments. * The Union Cabinet, on April 26, 2023, approved the National Medical Devices Policy, 2023, which is expected to facilitate the growth of the medical device sector to meet the public health objectives of access, affordability, quality, and innovation. * The PLI scheme for pharmaceuticals is being implemented with a total outlay of the Rs. 15,000 crore (US$ 2.04 billion) spanning from 2020-21 to 2028-29, to boost India's manufacturing capacity, elevate investment, and diversify product offerings in the sector. *Up to 100%, FDI has been allowed through automatic route for Greenfield pharmaceuticals projects. For Brownfield pharmaceuticals projects, FDI allowed is up to 74% through automatic route and beyond that through government approval. * The cumulative FDI equity inflow in the Drugs and Pharmaceuticals industry is US$ 22.52 billion during the period April 2000-March 2024, almost 3.4% of the total inflow received across sectors. * Indian pharma companies have a substantial share in the prescription market in the US and EU. The largest number of FDA-approved plants outside the US is in India. *In the Interim Budget 2024-25, the government earmarked Rs. 1,000 crore (US$ 120 million) for the promotion of bulk drug parks for FY25, a significant increase from the previous year. 

 The domestic pharmaceutical retail market grew 11% in July, driven by high sales of anti-infectives and pain relief products. The domestic pharmaceutical retail market grew 11% in July, driven by high sales of anti-infectives and pain relief products. India's wholesale inflation dropped to 2.04% in July, a 3-month low, down from June's 3.36%, driven by a sharp reduction in food price inflation, which fell to 3.45% from 10.87%. India's wholesale inflation dropped to 2.04% in July, a 3-month low, down from June's 3.36%, driven by a sharp reduction in food price inflation, which fell to 3.45% from 10.87%. In July 2024, India's total exports were US$ 62.42 billion (up 2.81%), with April-July 2024 exports stood at US$ 261.47 billion. In July 2024, India's total exports were US$ 62.42 billion (up 2.81%), with April-July 2024 exports stood at US$ 261.47 billion. According to data from the Commerce Ministry, India's medicine exports to the US and Italy are increasing with India becoming the third-largest source of imported 'medicines for retail sale' in the US. According to data from the Commerce Ministry, India's medicine exports to the US and Italy are increasing with India becoming the third-largest source of imported 'medicines for retail sale' in the US. The Indian government has waived local clinical trial requirements for drugs and vaccines approved by major global regulators, expediting access to advanced medical treatments in India. The Indian government has waived local clinical trial requirements for drugs and vaccines approved by major global regulators, expediting access to advanced medical treatments in India. Indian pharma company have won around 40 per cent of all Abbreviated New Drug Approval (ANDA) from the US Food and Drug Administration (FDA) between january and july 2013. Union Minister of External Affairs, Dr. S. Jaishankar and Union Commerce an... Bharat Mobility Global Expo 2024

1 – 3 Feb 2024, Bharat Mandapam, ... India has been one of the fastest growing economies in the world and has demonstrated remarkable flexibility and adaptability. During the past few dec... The Indian manufacturing sector provides livelihood to more than 14 million people (43.4% of the workforce) and contributes ~16% to India’s GDP.... The Indian pharmaceutical industry has proved to be the major player in the domestic and international market. This supremacy has been achieved throug... In 2023, India emerged as the biggest gaming market globally with 568 milli... Fintech has evolved in India, changing how financial services work by using... India has set a target of achieving US$ 7 trillion GDP by 2030, for which g... All material, information, data, images or content on this website is

                    subject to copyright or other applicable intellectual property laws and no part of it can be

                    reproduced in any form (including paper or electronic form) without prior written consent and

                    approval from IBEF. Infringements are subject to prosecution under the applicable laws. For consent

                    related queries and conditions, please write to info.brandindia@ibef.org Copyright © 2010-2024 India Brand Equity Foundation  
 Not a member